Log in
Enquire now
Alzheon

Alzheon

Develops medicines for patients suffering from Alzheimer's disease and other neurological disorders.

OverviewStructured DataIssuesContributors

Contents

alzheon.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Drug development
Drug development
Neuroscience
Neuroscience
Therapeutics
Therapeutics
Healthcare
Healthcare
Pharmaceutical industry
Pharmaceutical industry
Biomedical engineering
Biomedical engineering
Technology
Technology
...
Location
Framingham, Massachusetts
Framingham, Massachusetts
0
Lexington, Massachusetts
Lexington, Massachusetts
B2X
B2B
B2B
0
B2C
B2C
0
CEO
‌
Martin Tolar
0
Founder
‌
Martin Tolar
0
AngelList URL
angel.co/company/alzheon
Pitchbook URL
pitchbook.com/profiles.../60053-68
Legal Name
Alzheon, Inc.
Date Incorporated
2013
Number of Employees (Ranges)
11 – 50
Phone Number
+150886177090
Number of Employees
220
Full Address
111 Speen Street, Suite 306 Framingham, MA 01701 USA0
CIK Number
1,582,6360
Place of Incorporation
Delaware
Delaware
0
Investors
National Institute on Aging
National Institute on Aging
Ally Bridge Group
Ally Bridge Group
DUNS Number
0791807750
IRS Number
3,074,1490
Founded Date
2013
Total Funding Amount (USD)
92,660,000
Latest Funding Round Date
September 2020
Board of Directors
‌
Cristopher Noel Dunn
0
‌
Neil Flanzraich
0
‌
Diane Jorkasky
0
‌
Jordan Heller
0
‌
Martin Tolar
0
CFO
‌
Kenneth Mace
0
Latest Funding Type
Series B
Series B
CAGE Code
70HQ70
Wellfound ID
alzheon
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Contact Page URL
alzheon.com/developin...lzheimers/
Latest Funding Round Amount (USD)
2,400,000
SIC Code
2,8340
Wikidata ID
Q39052964

Alzheon is a privately held clinical stage, biotechnology company based in Framingham, Massachusetts that was founded in 2013 by Martin Tolar. It focuses on developing medications by directly addressing the underlying pathology of neurodegenerative disorders.

Products
ALZ-801

The company's lead product candidate is ALZ-801, a patented, orally administered prodrug of tramiprosate that is designed to inhibit amyloid oligomer formation, a key driver of Alzheimer's disease.

APOE4

The product is intended to focus on patients with mild Alzheimer's with the APOE4 genotype. It has been granted Fast Track Designation by the FDA in October 2017. Phase 3 clinical trials are planned for 2019.

ALZ-1903

Alzheon's product pipeline also has ALZ-1903, a pre-clinical candidate with the potential to inhibit amyloid misfolding.

Funding
Venture

On January 9, 2015 Alzheon completed a venture capital round with $3.1 million in funding from undisclosed investors.

Series A

On April 8, 2015 Alzheon completed their series A funding round with $10 million in funding from Ally Bridge Group (lead investor) and Scott H. Cohen.

Series B

On June 9, 2017 Alzheon is a completed their series B funding round with $15.8 million in funding from Ally Bridge Group.

Initial public offering

In April 2018, the company planned an $80 million IPO, but soon withdrew the offer. It re-announced later in August a $40 million IPO. However, that too was withdrawn in January 2019.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801

https://www.businesswire.com/news/home/20180723005050/en/Alzheon-Presents-New-Findings-APOE44-Homozygous-Patients

Web

What Happened? Alzheon Leaves IPO on the Table for the Second Time | BioSpace

Alex Keown

https://www.biospace.com/article/alzheon-withdraws-a-second-ipo/

Web

References

Find more companies like Alzheon

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.